Pharma Focus Asia

Taysha Plans New CGMP Gene Therapy Manufacturing Facility

Introduction:

Taysha Gene Therapies, Inc  plans for the construction of new current Good Manufacturing Practices (cGMP) facility with an investment of US$75 million. The facility will be situated at Durham, North Carolina.

Features:

The CGMP manufacturing facility is designed with an area covering 87,000-square-foot to support preclinical and commercial production of gene therapy pipeline. In addition, it also includes analytical, manufacturing and quality control testing capabilities for gene therapies.

The facility planned with 2000 litres capacity will support the scalable manufacturing of gene therapy material and meet the clinical and commercial demand.

This state-of-the-art facilitywill serve as a center of excellence for the development of gene therapies and complement the current capabilities by ensuring long term supply chain.

It is expected that the new manufacturing facility with multiple production suites will start its operations in 2023. The new project is anticipated to create nearly 200 jobs over two and a half years.

Specifications:

NameTaysha Gene Therapies, Inc
TypeNew Construction
BudgetUS$75 million
Year2023
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference